Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.

Also called NCT05180773

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05180773
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05180773. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-27 (actual); primary completion 2028-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Acronym
REBIRTH
Condition
Peripartum Cardiomyopathy, Postpartum
Intervention (Drug)
Bromocriptine
Intervention (Drug)
Placebo
Intervention (Drug)
Guideline Directed Medical Therapy for Heart Failure (GDMT)
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Second Placebo
Lead sponsor
Dennis M. McNamara, MD, MS (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct05180773
Content hash
3cddeacc9c0e8a2607cc9284a71ce387dc8ad0d748e223ddb5d9cb9662cb3197